Drugs / BGC20-1531
BGC20-1531
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00888680 | — | migraine disorder | Boston Scientific Corporation | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00957983 Comparator | Aug 2009 → Feb 2010 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGC20-1531 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00957983 ↗ |
| Known as | AP-1531 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1628698 ↗ |
| Known as | PGN 1531 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1628698 ↗ |
| Action | Inhibit | “EP-4 receptor antagonist” NCT00957983 ↗ |
| Modality | Small molecule | “new chemical entity, BGC20-1531” NCT00888680 ↗ |
| Route | Oral | “BGC20-1531 administered orally” NCT00888680 ↗ |